Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Hims & Hers launches new peptide treatments — while admitting there's more to learn about efficacy

The telehealth company will now offer compounded forms of sermorelin, glutathione, NAD+, vitamin B-12 and L-carnitine, none of which are approved by the FDA.

We haven't written up this one. CNBC has the full story — the link below goes straight to it.

Read the original at cnbc.com →

More in Finance & Markets

More from Wednesday 18 November →